Article Text

Download PDFPDF
Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study

Statistics from Altmetric.com

Footnotes

  • Funding Mitsubishi Tanabe Pharma Corporation sponsored this clinical trial and was responsible for the collection and analysis of data.

  • Patients consent Obtained.

  • Ethics approval This study was conducted with the approval of the local ethics committees of every participant centre.

  • Competing interests TT has received lecture fees from Abbott Japan, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis, Pfizer Japan and Takeda Pharmaceutical. NM has received grant support from Abbott Japan, Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Takeda Pharmaceutical; and lecture fees from Benesis and Otsuka Pharmaceutical. YT, T Yano and T Yoshinari are employees of Mitsubishi Tanabe Pharma. TA has no conflicts of interest. TK has received lecture fees from Abbott Japan, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Otsuka Pharmaceutical, Pfizer and Takeda Pharmaceutical.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.